KRTX News and Press, Karuna Therapeutics Inc. From 02/05/24

2024-02-05 04:01:47 ET Summary Bristol-Myers Squibb is pursuing aggressive M&A to address its growth challenges and loss of exclusivity for its top-selling drug Revlimid, ahead of more expirations due. The company's net debt load is substantial, and it relies heavily on a few ...

2024-02-01 16:30:02 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: Don't Waver Over Undue Fears And Doubts Bristol Myers Squibb: Might Be Approaching A Bottom In 2024 Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal U.S. govt. ...

2024-01-31 03:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

2024-01-25 04:45:00 ET Summary Patient Capital Management are long-term, contrarian, value investors focusing on growing wealth through Time, not Timing. We operate with the singular purpose of serving clients and helping them enhance their long term investment returns. The strate...

2024-01-22 14:37:43 ET More on Bristol-Myers Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also Bristol-Myers Squibb Company (BMY) J.P. Morgan 42nd Annual Healthcare Conference...

2024-01-21 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global growth equities...

NEW YORK, NY / ACCESSWIRE / January 20, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Karuna Therapeutics, Inc. (NASDAQ:...

NEW YORK, NY / ACCESSWIRE / January 17, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Karuna Therapeutics, Inc. (NASDAQ:...

NEW YORK, NY / ACCESSWIRE / January 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc. (NYSE:PGTI)'s ...